酮咯酸改善急性A型主动脉夹层患者预后的安全性和有效性:一项随机双盲安慰剂对照研究方案
本研究为单中心随机双盲安慰剂对照研究方案,拟纳入120例急性A型主动脉夹层患者,按1:1随机分为酮咯酸组与安慰剂组。酮咯酸组于术前2小时内肌内注射酮咯酸氨丁三醇60 mg/2 ml,术后第1天和第2天肌内注射30 mg/1 ml每日两次;安慰剂组给予同剂量、同剂型、同时间的0.9%氯化钠注射液。主要终点为药物相关不良事件的复合终点事件,次要终点包括药物相关不良事件、血液实验室检查、诊断影像学检查、临床生物标志物等。
要点
- 拟纳入120例急性A型主动脉夹层患者,1:1随机分为酮咯酸组和安慰剂组。
- 酮咯酸组术前2小时内肌内注射60 mg/2 ml,术后第1、2天肌内注射30 mg/1 ml每日两次。
- 主要终点为药物相关不良事件的复合终点事件。
核心结论
- 研究假说为酮咯酸治疗急性A型主动脉夹层患者可满足安全性指标并有效改善患者预后。
研究设计与样本
- 单中心、随机、双盲、安慰剂对照研究,拟招募120例急性A型主动脉夹层患者,按1:1随机分为酮咯酸组和安慰剂组。
主要发现
- 酮咯酸组于术前2小时内肌内注射酮咯酸氨丁三醇60 mg/2 ml,术后第1天和第2天肌内注射30 mg/1 ml每日两次;安慰剂组给予同剂量、同剂型、同时间的0.9%氯化钠注射液。
- 主要终点为药物相关不良事件的复合终点事件。
- 次要终点包括药物相关不良事件、血液实验室检查、诊断影像学检查、临床生物标志物等。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute type A aortic dissection (aTAAD) is a critical and life-threatening condition. Previous research has demonstrated that the use of ketorolac not only reduces the progression, incidence, and severity of aortic aneurysms in animal models, but also decreases postoperative mortality and complications in patients undergoing open abdominal aortic aneurysm replacement. However, there is a lack of studies investigating the efficacy of ketorolac in treating aTAAD in humans. Therefore, we conducted a study to evaluate the safety and efficacy of ketorolac in patients with aTAAD. Our hypothesis was that ketorolac treatment for aTAAD patients would meet safety indicators and effectively improve patient prognosis. METHODS/DESIGN: This study is a single-center, randomized, double-blinded, and placebo-controlled study. A total of 120 patients with aTAAD will be recruited and will be randomized into the ketorolac group and placebo group with a ratio of 1:1. Ketorolac tromethamine 60 mg per 2 ml will be intramuscularly injected within 2 h before surgery, followed by intramuscular injections of 30 mg per 1 ml BID. on the first and second postoperative days in the Ketorolac group, while 0.9% saline will be administered at the same dose, dosage form, and time in the placebo group. This study aims to evaluate the safety and efficacy of ketorolac in improving the prognosis of aTAAD. The primary endpoint is the composite endpoint event concerning drug-related adverse events. Secondary endpoints include drug-related adverse events, laboratory examination of blood, diagnostic imaging tests, clinical biomarkers, etc. DISCUSSION: This study has been approved by the Medical Ethics Committee of Affiliated Nanjing Drum Tower Hospital, Nanjing University Medical College (approval number: 2023-197-02). This study is designed to evaluate the safety and efficacy of ketorolac in patients with aTAAD. All participating patients will sign an informed consent form, and the trial results will be published in international peer-reviewed journals. TRIAL REGISTRATION: The Chinese Clinical Trial Registry ( http://www.chictr.org.cn ) ChiCTR2300074394. Registered on 4 October 2023.
引用
- Lv Z, Pan T, Zhang H, et al. Safety and efficacy of ketorolac in improving the prognosis of acute type A aortic dissection patients: a protocol of a randomized, double-blinded, and placebo-controlled study. Trials. 2024. PMID: 38600561. doi:10.1186/s13063-024-08093-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。